[5] He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med....
Treatment of stage III NSCLC and sedation of pathological conditions associated with the treatmentThe present disclosure is generally used in methods for treating untreated patients diagnosed with stage III non-small cell lung cancer (NSCLC) and / or for calming the pathological condition associated ...
[2] Harris JP, et al. Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations. Clin Lung Cancer. 2022 Jun;23(4):333-344. [3] Huber RM, ...
[2] Harris JP, et al. Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations. Clin Lung Cancer. 2022 Jun;23(4):333-344. [3] Huber RM, et al. Interdisciplinary multimodality management of stage II...
treatment in adults for your lung cancer to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery and you have received platinum-based chemotherapy, and you have stage IB and your tumor(s) is 4 cm or greater in size, stage II, or stage IIIA ...
performance status. For some of these patients, just introducing a platinum—cisplatin with another drug or carboplatin/paclitaxel weekly—might bring a huge benefit to our experiences. That’s why we might still be aggressive in these populations when they progress beyond the immune treatment arm....
TREATMENT of lung tumorsLUNG cancer treatmentTHERAPEUTIC use of antineoplastic agentsLUNG cancerSURVIVALLUNG tumorsTUMOR classificationCOMBINED modality therapyFor stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up to 5 years, with decreasing 5-year survival rates ...
Should I see an oncologist to discuss a treatment plan after surgery? What does “resectable” mean? What’s the difference between “early-stage” and “resectable” NSCLC? What does “resectable” mean? What’s the difference between “early-stage” and “resectable” NSCLC?
radical treatment? Stage 3A NSCLC – are we offering enough radical treatment?Stage 3A NSCLC – are we offering enough radical treatment?doi:10.1016/S0169-5002(18)30157-0J. PriceP. JainP. BeckettLung Cancer
≤10% viable tumor in lung and lymph nodes). The overall response rate was 53.6% for nivolumab/chemotherapy versus 37.4% with chemotherapy alone. Surgery was done for 83% of patients receiving nivolumab/chemotherapy versus 7...